Inventor
DONAHOE PATRICIA K
US27 patents
⚠️ This page may combine multiple inventors who share the name “DONAHOE PATRICIA K”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GEN HOSPITAL CORP
14 patentsUS6692738B2Feb 17, 2004
Delivery of therapeutic biologicals from implantable tissue matrices
GEN HOSPITAL CORP202 citations97
US5538892AJul 23, 1996
Nucleic acids encoding a TGF-β type 1 receptor
GEN HOSPITAL CORP83 citations95
US5547854AAug 20, 1996
DNA encoding a receptor for Mullerian inhibitory substance, misr1, and corresponding vectors, cells, probes, and recombinant methods
GEN HOSPITAL CORP42 citations94
US5010055AApr 23, 1991
Use of EGF to reverse the contraceptive activity of MIS
GEN HOSPITAL CORP23 citations92
US7078032B2Jul 18, 2006
Delivery of therapeutic biologicals from implantable tissue matrices
GEN HOSPITAL CORP17 citations91
US5661126AAug 26, 1997
Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
GEN HOSPITAL CORP49 citations91
US5198420AMar 30, 1993
Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome
GEN HOSPITAL CORP53 citations91
US4487833ADec 11, 1984
Method of preparing hybridomas and of purifying immunogenic materials
GEN HOSPITAL CORP27 citations89
US6673352B1Jan 6, 2004
Use of Mullerian inhibiting substance for treating excess androgen states
GEN HOSPITAL CORP18 citations87
US4510131AApr 9, 1985
Purified Mullerian Inhibiting Substance and method of use
GEN HOSPITAL CORP20 citations81
US4792601ADec 20, 1988
Monoclonal antibody to mullerian inhibiting substance
GEN HOSPITAL CORP20 citations79
US5011687AApr 30, 1991
Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells
GEN HOSPITAL CORP15 citations73
US5310880AMay 10, 1994
Purification of Mullerian inhibiting substance
GEN HOSPITAL CORP12 citations71
US5912224AJun 15, 1999
Methods and compositions for enhancing cellular response to TGF-β ligands
GEN HOSPITAL CORP14 citations68
MASSACHUSETTS GEN HOSPITAL
8 patentsUS4404188ASep 13, 1983
Purified Mullerian Inhibiting Substance and method of purification
MASSACHUSETTS GEN HOSPITAL36 citations91
US11135269B2Oct 5, 2021
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
MASSACHUSETTS GEN HOSPITAL3 citations70
US12486309B2Dec 2, 2025
Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
MASSACHUSETTS GEN HOSPITAL0 citations60
US11998590B2Jun 4, 2024
Use of Mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
MASSACHUSETTS GEN HOSPITAL0 citations60
US11518793B2Dec 6, 2022
Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
MASSACHUSETTS GEN HOSPITAL0 citations60
US12497437B2Dec 16, 2025
Modified Mullerian Inhibiting Substance (MIS) proteins and uses thereof for the treatment of diseases
MASSACHUSETTS GEN HOSPITAL0 citations57
US11084860B2Aug 10, 2021
Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
MASSACHUSETTS GEN HOSPITAL0 citations57
US10258668B2Apr 16, 2019
Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
MASSACHUSETTS GEN HOSPITAL0 citations48